Cancer Sci 2019 Feb 12;110(2):707-716. Epub 2018 Dec 12.
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Studies have indicated an association between UDP-glucuronosyltransferase-1A1 (UGT1A1) genetic polymorphisms and irinotecan-induced toxicity. We undertook this study to investigate the association between UGT1A1 genetic polymorphisms and toxicity in patients treated with the FOLFIRINOX (comprising oxaliplatin, irinotecan, fluorouracil, and leucovorin) chemotherapy regimen in the JASPAC 06 study. Patients screened for UGT1A1*6 and UGT1A1*28, and treated with either the original FOLFIRINOX (oxaliplatin 85 mg/m , irinotecan 180 mg/m , leucovorin 200 mg/m , bolus 5-fluorouracil [5-FU] 400 mg/m , and continuous 5-FU 2400 mg/m ) or a modified FOLFIRINOX (oxaliplatin 85 mg/m , irinotecan 150 mg/m , leucovorin 200 mg/m , and continuous 5-FU 2400 mg/m ) as first-line chemotherapy were included. Read More